Print

HOPE: Olaparib, Palbociclib and Fulvestrant for BRCA-Associated, ER/PR-Positive, Her2-Negative Metastatic Breast Cancer

https://www.facingourrisk.org/research-clinical-trials/study/147/olaparib-palbociclib-and-fulvestrant-for-brca-associated-erpr-positive-her2-negative-metastatic-breast-cancer

Clinicaltrials.gov identifier:
NCT03685331 (https://clinicaltrials.gov/show/NCT03685331)


Study Contact Information:

Contact: Payal D. Shah, MD by phone:  855-216-0098
Alexandra Torres by phone: 855-216-0098
or Email: [email protected]  

About the Study

The goal of this study is to find the best dose and measure side effects of palbociclib when given together with olaparib and fulvestrant, in treating people with hormone receptor-positive (HR+), HER2-negative metastatic breast cancer who have a BRCA1 or BRCA2 mutation. Palbociclib and Olaparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Fulvestrant is a type of treatment that may prevent breast cancer cell growth by blocking estrogen and progesterone receptor stimulation.

This study is no longer enrolling people.

This Study is Open To:

This study is no longer enrolling people.

This Study is Not Open To:

This study is no longer enrolling people.

About FORCE

FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.